{"id":516999,"date":"2021-07-23T07:51:01","date_gmt":"2021-07-23T11:51:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/"},"modified":"2021-07-23T07:51:01","modified_gmt":"2021-07-23T11:51:01","slug":"medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/","title":{"rendered":"Medigus: Polyrizon\u2019s innovative proprietary technology found effective against coronavirus in a pre-clinical study"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Polyrizon\u2019s formulations demonstrated high efficacy by preventing coronavirus from interacting with epithelial host cells and by inhibiting cells&#8217; death <\/em>\n      <\/p>\n<p>OMER, Israel, July  23, 2021  (GLOBE NEWSWIRE) &#8212; \u00a0Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company (which Medigus owns 33.24% of its share capital) engaged in developing highly differentiated biological gels for the purpose of protecting patients against biological threats and external pathogens, reported pre-clinical data from its previously announced pre-clinical study showing that its proprietary technology has the potential to reduce the risk of an infection with Human coronavirus and may also prevent COVID-19. Polyrizon develops an innovative technology, designed to safely prevent allergens and virus intrusion through the upper airways and eye cavities. Polyrizon\u2019s technology is comprised of a bio-gel that is applied topically, and can be formulated both for wet and dry administration.<\/p>\n<p align=\"justify\">Polyrizon\u2019s cell-culture study was conducted in Israel and lasted one month. The trial tested a number of different formulations of its highly differentiae biological gel comparing to controlled groups for protection against coronavirus, and screening several new formulations designed to prevent coronavirus from effecting epithelial cells. <\/p>\n<p align=\"justify\">Data from Polyrizon\u2019s cell-culture study confirms that its innovative product works in a dose-dependent manner to effectively reduce the infection of cells from the human coronavirus 229E, a species of coronavirus which infects humans and associated with a range of respiratory symptoms, ranging from the common cold to high-morbidity outcomes such as pneumonia and bronchiolitis. <\/p>\n<p align=\"justify\">Polyrizon tested a few prototypes of its lead platform against Covid-19 viruses. In these studies, the products demonstrated high efficacy over the controlled groups by preventing coronavirus from effecting epithelial host cells and by inhibiting cells&#8217; death. In addition, the product shows a very good safety profile in a cell toxicity studies, together with broad spectrum activity against different viruses and other biological threats. <\/p>\n<p align=\"justify\">These pre-clinical data highlight the effect that Polyrizon\u2019s product can provide against SARS-CoV-2 and a variety of different respiratory viruses such as cold and flu.<\/p>\n<p align=\"justify\">Polyrizon is planning clinical trials for its products subject to receipt of regulatory approvals. The first efficacy results are currently expected within the next 12 months. <\/p>\n<p>\n        <strong>About Medigus<\/strong>\n      <\/p>\n<p align=\"justify\">Medigus is traded on the Nasdaq Capital Market. To learn more about the company\u2019s advanced technology, please visit\u00a0<u>http:\/\/www.medigus.com\/investor-relations.<\/u><\/p>\n<p>\n        <strong>Cautionary Note Regarding\u00a0Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>This press release may contain statements that are \u201cForward-Looking Statements,\u201d which are based upon the current estimates, assumptions and expectations of Medigus\u2019 management and its knowledge of the relevant market. The company has tried, where possible, to identify such information and statements by using words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cenvision,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d \u201ccontemplate\u201d and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. For example, Medigus uses forward looking statements when describing the timing of future clinical results and Polyrizon\u2019s <\/em><br \/>\n        <em>formulations as there is no assurance on whether future trials\u2019 results and Polyrizon\u2019s regulatory process and pathway will be successful. These forward-looking statements represent Medigus\u2019 expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of the Medigus\u2019 activity to differ significantly from the content and implications of such statements. Other risk factors affecting Medigus and Polyrizon are discussed in detail in the Medigus\u2019 filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and Medigus undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither Medigus nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Medigus\u2019 securities. Nothing in this press release should be deemed to be medical or other advice of any kind\u00a0<\/em>\n      <\/p>\n<p>\n        <strong>Contact (for media only)<\/strong>\n      <\/p>\n<p>Tali Dinar <br \/> Chief Financial Officer<br \/> +972-8-6466-880<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-3zAwnoDgStITaKpN07y8ZQWha-mpcX7jOzclHM9g5nEzf6SqAe4JBpNT0kfeQhzAlXKdcm3A5_BoHP94jLUZw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>ir@medigus.com<\/u><\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTc0MyM0MzExOTgzIzUwMDA2NDMzMQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/6129dd52-7919-4a21-98d4-1ddd0668cb12\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Polyrizon\u2019s formulations demonstrated high efficacy by preventing coronavirus from interacting with epithelial host cells and by inhibiting cells&#8217; death OMER, Israel, July 23, 2021 (GLOBE NEWSWIRE) &#8212; \u00a0Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company (which Medigus owns 33.24% of its share capital) engaged in developing highly differentiated biological gels for the purpose of protecting patients against biological threats and external pathogens, reported pre-clinical data from its previously announced pre-clinical study showing that its proprietary technology has the potential to reduce the risk of an infection with Human coronavirus and may also prevent COVID-19. Polyrizon develops an innovative &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Medigus: Polyrizon\u2019s innovative proprietary technology found effective against coronavirus in a pre-clinical study&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-516999","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Medigus: Polyrizon\u2019s innovative proprietary technology found effective against coronavirus in a pre-clinical study - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medigus: Polyrizon\u2019s innovative proprietary technology found effective against coronavirus in a pre-clinical study - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Polyrizon\u2019s formulations demonstrated high efficacy by preventing coronavirus from interacting with epithelial host cells and by inhibiting cells&#8217; death OMER, Israel, July 23, 2021 (GLOBE NEWSWIRE) &#8212; \u00a0Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company (which Medigus owns 33.24% of its share capital) engaged in developing highly differentiated biological gels for the purpose of protecting patients against biological threats and external pathogens, reported pre-clinical data from its previously announced pre-clinical study showing that its proprietary technology has the potential to reduce the risk of an infection with Human coronavirus and may also prevent COVID-19. Polyrizon develops an innovative &hellip; Continue reading &quot;Medigus: Polyrizon\u2019s innovative proprietary technology found effective against coronavirus in a pre-clinical study&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-23T11:51:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTc0MyM0MzExOTgzIzUwMDA2NDMzMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medigus: Polyrizon\u2019s innovative proprietary technology found effective against coronavirus in a pre-clinical study\",\"datePublished\":\"2021-07-23T11:51:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\\\/\"},\"wordCount\":748,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NTc0MyM0MzExOTgzIzUwMDA2NDMzMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\\\/\",\"name\":\"Medigus: Polyrizon\u2019s innovative proprietary technology found effective against coronavirus in a pre-clinical study - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NTc0MyM0MzExOTgzIzUwMDA2NDMzMQ==\",\"datePublished\":\"2021-07-23T11:51:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NTc0MyM0MzExOTgzIzUwMDA2NDMzMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NTc0MyM0MzExOTgzIzUwMDA2NDMzMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medigus: Polyrizon\u2019s innovative proprietary technology found effective against coronavirus in a pre-clinical study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medigus: Polyrizon\u2019s innovative proprietary technology found effective against coronavirus in a pre-clinical study - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/","og_locale":"en_US","og_type":"article","og_title":"Medigus: Polyrizon\u2019s innovative proprietary technology found effective against coronavirus in a pre-clinical study - Market Newsdesk","og_description":"Polyrizon\u2019s formulations demonstrated high efficacy by preventing coronavirus from interacting with epithelial host cells and by inhibiting cells&#8217; death OMER, Israel, July 23, 2021 (GLOBE NEWSWIRE) &#8212; \u00a0Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company (which Medigus owns 33.24% of its share capital) engaged in developing highly differentiated biological gels for the purpose of protecting patients against biological threats and external pathogens, reported pre-clinical data from its previously announced pre-clinical study showing that its proprietary technology has the potential to reduce the risk of an infection with Human coronavirus and may also prevent COVID-19. Polyrizon develops an innovative &hellip; Continue reading \"Medigus: Polyrizon\u2019s innovative proprietary technology found effective against coronavirus in a pre-clinical study\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-23T11:51:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTc0MyM0MzExOTgzIzUwMDA2NDMzMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medigus: Polyrizon\u2019s innovative proprietary technology found effective against coronavirus in a pre-clinical study","datePublished":"2021-07-23T11:51:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/"},"wordCount":748,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTc0MyM0MzExOTgzIzUwMDA2NDMzMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/","name":"Medigus: Polyrizon\u2019s innovative proprietary technology found effective against coronavirus in a pre-clinical study - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTc0MyM0MzExOTgzIzUwMDA2NDMzMQ==","datePublished":"2021-07-23T11:51:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTc0MyM0MzExOTgzIzUwMDA2NDMzMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTc0MyM0MzExOTgzIzUwMDA2NDMzMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medigus-polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medigus: Polyrizon\u2019s innovative proprietary technology found effective against coronavirus in a pre-clinical study"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=516999"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516999\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=516999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=516999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=516999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}